Shandong Sinobioway Biomedicine Co., Ltd. (002581) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shandong Sinobioway Biomedicine Co., Ltd.

Why is Shandong Sinobioway Biomedicine Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Poor long term growth as Net Sales has grown by an annual rate of -11.60% and Operating profit at -7.87% over the last 5 years

Negative results in Mar 25

INTEREST(HY) At CNY 0.2 MM has Grown at 1,175.81%
NET SALES(Q) Lowest at CNY 33.89 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -35.28%, its profits have risen by 30.4%

Underperformed the market in the last 1 year

Even though the market (China Shanghai Composite) has generated returns of 15.18% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -35.28% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shandong Sinobioway Biomedicine Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Shandong Sinobioway Biomedicine Co., Ltd.

-45.29%

-0.41

51.96%

China Shanghai Composite

14.77%

1.01

15.10%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-11.60%

EBIT Growth (5y)

-7.87%

EBIT to Interest (avg)

-31.32

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.23

Sales to Capital Employed (avg)

0.17

Tax Ratio

13.80%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

2.48%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.72

EV to EBIT

-10.87

EV to EBITDA

-12.85

EV to Capital Employed

1.95

EV to Sales

12.80

PEG Ratio

Dividend Yield

ROCE (Latest)

-17.93%

ROE (Latest)

-11.06%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

NET PROFIT(HY)

Higher at CNY -188.79 MM

DEBT-EQUITY RATIO (HY)

Lowest at -23.19 %

RAW MATERIAL COST(Y)

Fallen by -12.1% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 2.02%

-17What is not working for the Company

INTEREST(HY)

At CNY 0.2 MM has Grown at 1,175.81%

NET SALES(Q)

Lowest at CNY 33.89 MM

Here's what is working for Shandong Sinobioway Biomedicine Co., Ltd.

Net Profit

Higher at CNY -188.79 MM

than preceding 12 month period ended Mar 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Net Profit

At CNY -188.79 MM has Grown at 51.58%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Debt-Equity Ratio

Lowest at -23.19 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Inventory Turnover Ratio

Highest at 2.02%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -12.1% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shandong Sinobioway Biomedicine Co., Ltd.

Interest

At CNY 0.2 MM has Grown at 1,175.81%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales

At CNY 33.89 MM has Fallen at -61.71%

over average net sales of the previous four periods of CNY 88.51 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (CNY MM)

Net Sales

Lowest at CNY 33.89 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)